Drug – bio-affecting and body treating compositions – Preparations characterized by special physical form – Cosmetic – antiperspirant – dentifrice
Reexamination Certificate
2006-03-21
2006-03-21
Page, Thurman K. (Department: 1615)
Drug, bio-affecting and body treating compositions
Preparations characterized by special physical form
Cosmetic, antiperspirant, dentifrice
C424S464000, C514S152000
Reexamination Certificate
active
07014858
ABSTRACT:
A method of treating telangiectasia in a human in need thereof comprising administering to said human a tetracycline compound in an amount that is effective to treat telangiectasia, but has substantially no antibiotic activity.
REFERENCES:
patent: 5122519 (1992-06-01), Ritter
patent: 5505949 (1996-04-01), Benitez
patent: 5674539 (1997-10-01), Tomas et al.
patent: 5827840 (1998-10-01), Ramamurthy et al.
patent: 5908838 (1999-06-01), Gans
patent: 5998390 (1999-12-01), Ramamurthy et al.
patent: 6015803 (2000-01-01), Wirostko
patent: 6133310 (2000-10-01), Parks
patent: 6664287 (2003-12-01), Avery et al.
patent: 0 410 099 (1991-01-01), None
patent: WO 83/00628 (1983-03-01), None
patent: WO 99/58131 (1999-11-01), None
Akamatsu, et al. “Effect of Keigai-Rengyo-To, a Japanese Kampo Medicine, on Neutorphil Functions: a Possible Mechanism of Action of Keigai-Rengyo-To in Acne,”The Journal of International Medical Research, 25:255-265 (1997).
Baer, et al. “High-Dose Tetracycline Therapy in Severe Acne,”Arch Dermatol, 112:479-481 (Apr. 1976).
Cheryl Guttman, “Emerging resistance changes face of antibiotic therapy for acne,”Dermatology Times,Jan. 2001, p. 22.
Hirohiko Akamatsu, Maki Asada, Jinro Komurra, Yasuo Asada, and Yukie Niwa, “Effect of Doxycycline on the Generation of Reactive Oxygen Species: A Possible Mechanism of Action of Acne Therapy with Doxycycline,”Acta Derm Venereol(Stockh)72:178-178 (1992).
Bodokh, Y. Jacomet, J. Ph. Lacour and J.P. Ortonne, “Minocycline Induces an Increase in the Number of Excreting Pilosebaceous Follicles in Acne Vulgaris,”Acta Derm Venereol(Stockh)77:255-259 (1997).
W. J. Cunliffe, M.D., F.R.C.P., “Evolution of a Strategy for the Treatment of Acne, ”Acad Dermatol, 16:591-9 (1987).
E. Anne Eady, Eileen Ingham, Christina E. Walters, Jonathan H. Cove, and William J. Cunliffe, “Modulation of Comedonal Levels of Interleukin-1 in Acne Patients Treated with Tetracyclines,”J. Invest Dermatol, 101:86-91 (1993).
Boni E. Elewski, M.D., Beth A.J. Lamb, W. Mitchell Sams, Jr., M.D., and W. Ray Gammon, M.D., “In Vivo Suppression of Neutrophil Chemotaxis by Systemically and Topically Administered Tetracycline,”J Am Acad Dermatol, 8:807-812 (1983).
Nancy B. Esterly, M.D., Nancy L. Furey, M.D., and Lillian E. Flanagan, B.S., “The Effect of Antimocrobial Agents on Leukocyte Chemotaxis,”The Journal of Investigative Dermatology, 70(1):51-55 (1978).
Sainte-Marie, I. Tenaud, O. Jumbou and B. Dréno, “Minocycline Modulation of Alpha-MSH Production by Keratinocytes In vitro,”Acta Derm Venereol 79:265-267 (1999).
Hoshiki Miyachi, M.D., Akira Yoshioka, M.D., Sadao Imamura, M.D., and Yukie Niwa, M.D., “Effect of Antibiotics on the Generation of Reactive Oxygen Species,”J Invest Dermatol, 86(4):449-453 (1986).
Gerd Plewig, M.D., and Erwin Schöpf, M.D., “Anti-Inflammatory Effects of Antimicrobial Agents: An In Vivo Study,”The Journal of Investigative Dermatology, 65:532-536 (1975).
M. Toyoda and M. Morohashi, “An Overview of Topical Antibiotics for Acne Treatment,”Dermatology, 196:130-134 (1998).
Sheila E. Unkles, and Curtis G. Gemmell, “Effect of Clindamycin, Erythromycin, Lincomycin, and Tetracycline on Growth and Extracellular Lipase Production by Propionibacteria In Vitro,”Antimicrobial Agents and Chemotherapy, 21:39-43 (1982).
G.F. Webster, K.J. McGinley, and J.J. Leyden, “Inhibition of Lipase Production inPropionibacterium acnesby Sub-Minimal-Inhibitory Concentrations of Tetracycline and Erythromycin,”British Journal of Dermatology, 104:453-457 (1981).
Guy F. Webster, M.D., Ph.D., Susan M. Toso, M.S., and Lutz Hegemann, M.D., Ph.D., “Inhibition of a Model of In Vitro Granuloma Formation by Tetracyclines and Ciprofloxacin,”Arch Dermatol., 130:748-752 (1994).
Reynold C. Wong, M.D., Sewon Kang, M.P.H., Jan L. Heezen, L.P.N. John J. Voorhees, M.D., and Charles N. Ellis, M.D., “Oral Ibuprofen and Tetracycline for the Treatment of Acne Vulgaris,”J Am Acad Dermatol, 11:1076-1081 (1984).
Kenneth S. Kornman and Edward H. Karl, “The Effect of Long-Term Low-Dose Tetracycline Therapy on the Subgingival Microflora in Refractory Adult Periodontitis,”J. Periodontol.53(10) 604-610 (Oct. 1982).
Bikowski, J.B., “Treatment of rosacea with doxycycline monohydrate,” Curtis. 2000 Aug., 66(2):149-152.
Jimenez-Acosta, “Response to tetracycline of telangiectasias in male hemophilliac with human immunodeficiency virus infection,” J. Am. Acad. Dermatol. Aug., 19, 1988(2 Pt 1):369-379.
Torresani, C., “Clarithromycin versus doxycycline in the treatment of rosaecea,” Int. J. Clin. Dermatol. Dec. 1997, 36(12):942-946.
McClellan, K.J., “Topical Metronidazole. A review of its use in rosaea,” Am. J. Clin. Dermatol. May-Jun. 2000, 1(3):191-199.
Quarterman, M.J., “Ocular Rosacea. Signs, symptoms and tear studies before and after treatment with doxycycline,” Arch. Dermatol. Jan. 1997, 133(1):49-54.
Skidmore et al., “Effects of Subantimicrobial-Dose Doxycycline in the Treatment of Moderate Acne,”Archives of Dermatology139:459-464 (Apr. 2003), XP009047590.
CollaGenex Pharmaceuticals, Inc.
Hoffmann & Baron , LLP
Page Thurman K.
Tran S.
LandOfFree
Use methods of treating acne and telangiectasia does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use methods of treating acne and telangiectasia, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use methods of treating acne and telangiectasia will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3595634